NCT00698243View on ClinicalTrials.gov

Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Any Solid Tumor or Lymphoma
Interventions
DRUG

OSI-027

Administered orally

Trial Locations (3)

3000

University Hospitals Leuven, Leuven

48201

Karmanos Cancer Institute, Detroit

SM2 5PT

Royal Mardsen Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY